Profile

Cover photo
Advaxis, Inc.
28 followers|13,045 views
AboutPostsPhotosYouTube

Stream

Advaxis, Inc.

Shared publicly  - 
 
Advaxis to Present at the 2015 Wells Fargo Securities Healthcare Conference. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Appoints Tom Ridge, America’s First Secretary of Homeland Security and 43rd Governor of Pennsylvania, to Board of Directors. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Two research projects involving Advaxis’s ADXS-PSA, being developed for prostate cancer, have been selected as 2015 Challenge Awards, sponsored by the Movember Foundation and the Prostate Cancer Foundation (PCF). View the announcement here: http://bit.ly/1KQtE1t
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis is pleased to announce CFO Sara Bonstein as a finalist for NJBIZ CFO of the Year. http://bit.ly/1ImS2br
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Appoints Dr. Shelonitda S. Rose as Vice President, Clinical Development. Take a look at the full announcement here: http://prn.to/1JU0XjE
1
Add a comment...
Have them in circles
28 people
Quinn Roberts (Quorum Review)'s profile photo
Jonah Samuels's profile photo
David Miller's profile photo
Vincent Grillo's profile photo
NAI500 Cwn's profile photo
Scott A's profile photo
Eduardo Zawadzki's profile photo
Liz Peters's profile photo
yolande lorijn's profile photo

Advaxis, Inc.

Shared publicly  - 
 
Phase 2 Study of Advaxis’s Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac (ADXS-HPV) in Combination with Durvalumab (MEDI4736) for the Treatment of HPV-Associated Cancers. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis is proud to partner with the Farrah Fawcett Foundation to recognize excellence in anal cancer research at the “Tex-Mex Fiesta” benefitting Stand Up to Cancer on Sept. 9. Read more here:
BEVERLY HILLS, Calif., Aug. 11, 2015 /PRNewswire/ -- Farrah Fawcett Foundation Presents First Annual 'Tex-Mex Fiesta' Benefitting Stand Up To Cancer;...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis’s Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015. See the full announcement here: bit.ly/1fHepNr
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2 - See more at: http://bit.ly/1MmmwN8
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Happy to announce that Advaxis’s president & CEO, Dan O'Connor, was recognized as the 2015 Ernst & Young Entrepreneur Of The Year® in New Jersey. Take a look at the full announcement here: http://bit.ly/1BRbETN
PRINCETON, N.J., June 29, 2015 /PRNewswire/ -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that its president and chief executive officer, Daniel O'Connor was selected as a winner in the 2015 Ernst & Young (EY) ...
1
Add a comment...
People
Have them in circles
28 people
Quinn Roberts (Quorum Review)'s profile photo
Jonah Samuels's profile photo
David Miller's profile photo
Vincent Grillo's profile photo
NAI500 Cwn's profile photo
Scott A's profile photo
Eduardo Zawadzki's profile photo
Liz Peters's profile photo
yolande lorijn's profile photo
Contact Information
Contact info
Phone
609-452-9813
Address
305 College Rd E‎ Princeton, NJ 08540
Story
Tagline
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Introduction

Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.